Opioid

SAMHSA’s updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. The toolkit also emphasizes that harm reduction and access to treatment are essential...

Background: People who have problems with using opioids or other drugs and inject them have shorter lives than most people. Liver diseases, especially, contribute to this. Checking liver stiffness might help find liver problems early. This...

Background Physical or mental health commorbidities are common among people with substance use disorders undergoing opioid agonist therapy. Exercise provides many health benefits and can be used both as a preventive and treatment strategy...

There is little study of lifetime trauma exposure among individuals engaged in medication treatment for opioid use disorder (MOUD). A multisite study provided the opportunity to examine the prevalence of lifetime trauma and differences by gender, PTSD status, and chronic pain.

Abstract Background The prevalence and associated overdose death rates from opioid use disorder (OUD) have dramatically increased in the last decade. Despite more available treatments than 20 years ago, treatment access and high...

Background People with opioid use disorder (OUD) are frequently in contact with the court system and have markedly higher rates of fatal opioid overdose. Opioid intervention courts (OIC) were developed to address increasing rates of opioid...

Purpose As deaths from the illicit drug poisoning crisis continue to rise in Canada, increasing the number of healthcare professionals qualified to effectively prescribe opioids could be beneficial. The willingness of family medicine...

Authors: Mohammad Jalali, PhD
Harvard University
Wayne Wakeland, PhD
Portland State University Abstract:
The opioid crisis is one of the most pressing public health issues in the U.S. today. Opioid overdoses are the proverbial “tip of the...

Abstract Importance Medication for opioid use disorder (MOUD) (eg, buprenorphine and naltrexone) can be offered in primary care, but barriers to implementation exist. Objective To evaluate an implementation intervention over 2 years to...